Effect of lipid-lowering therapy on vasomotion and endothelial function

1999 ◽  
Vol 1 (3) ◽  
pp. 238-243 ◽  
Author(s):  
Scott Kinlay ◽  
Jorge Plutzky
Keyword(s):  
Endothelial Function ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy

scholarly journals Lipid Lowering Therapy with Combination of Niacin and Statin in Women: Age-Related Endothelial Effects

2013 ◽  
Vol 2013 ◽  
pp. 1-7
Author(s):  
Beth Parker ◽  
Kamlesh Kothawade ◽  
Namee Kim ◽  
Maura Paul-Labrador ◽  
Noel Bairey Merz ◽  
...  
Keyword(s):  
Endothelial Function ◽  
Vascular Function ◽  
Controlled Trial ◽  
Pearson Correlation ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Cardiac Events ◽  
Double Blind ◽  
Lowering Therapy ◽  
Age Related

Background. Many women remain at risk for cardiac events despite treatment to reduce low-density lipoprotein cholesterol (LDL-C). We hypothesized that for postmenopausal women treated with niacin in addition to statin vascular function will improve. Methods. We conducted a randomized, double-blind, placebo-controlled trial of 16 weeks of niacin (N) versus placebo (PL) in 43 women (mean age, 67±9 years) previously on statin therapy. Study outcomes included lipoprotein levels, vascular inflammation assessed by high sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), and endothelial function, assessed as brachial artery flow mediated dilation (FMD). Results. The N group significantly increased HDL-C and decreased LDL-C cholesterol relative to PL (both P<0.01). FMD improved in both groups (P=0.02) irrespective of niacin (P=0.21). Age influenced change in FMD (P=0.01) such that improved FMD (before to after) with lipid lowering therapy was greater with older age (P=0.03 Pearson correlation = 0.34), independent of treatment group. Conclusions. Lipid lowering therapy with combination of niacin and statin does not improve inflammation or endothelial function compared to statin alone. However, older women demonstrate relatively greater endothelial benefit of lipid lowering therapy over 4 months. This trial is registered with Clinicaltrials.gov NCT00590629.

scholarly journals The influence of omega-3 polynenasic fatty acids on the pathogenetic lines of arterial hypertension in the person with abdominal obesity

2019 ◽  
pp. 55-57
Author(s):  
L.І. Vlasyk ◽  
V.K. Taschuk ◽  
H.I. Khrebtii
Keyword(s):  
Fatty Acids ◽  
Characteristic Feature ◽  
Endothelial Function ◽  
Polyunsaturated Fatty Acids ◽  
Abdominal Obesity ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy ◽  
Group I ◽  
Group Ii

Hypertriglyceridemia is a characteristic feature of dyslipidemia in hypertension in patients with concomitant abdominal obesity. These individuals constitute an increased risk of cardiovascular complications, so optimizing their treatment is extremely important medical problem. The aim is to study the dynamics of the major lipid spectrum of the blood vessels and endothelial function as a marker of atherosclerosis, when you connect to the drug ω-3 polyunsaturated fatty acids to the standard combination of antihypertensive and lipid-lowering therapy in patients with hypertension and abdominal obesity. The analysis of the dynamics of lipidohramy and vascular endothelial function in patients with essential hypertension and abdominal obesity during the 6-month standard (basic) antihypertensive (lisinopril, amlodipine) and lipid-lowering therapy (atorvastatin) (group I) and accession thereto ω-3 polyunsaturated fatty acids (group II). When analyzing the results of 6 months of treatment in the studied patient groups in triglycerides reduction was significantly more pronounced when using combination antihypertensive and lipid-lowering therapy (-40,9+3,1% in group II and -22,7+2,3% in group I, p<0,001). Also in group II was marked significantly greater increase in HDL cholesterol (38,6+2,5% in group II and 28,7+2,6% in group I, p<0,05) and improved endothelium vasodilation (9,86+0,28% in group II and 6,8+0,23%, p<0,01). Thus, in patients with hypertension and concomitant abdominal obesity observed significant dyslipidemia, a characteristic feature of which is hypertriglyceridemia. Joining the standard antihypertensive and lipid-lowering therapy ω-3 polyunsaturated fatty acids contributes significantly more effective normalization of triglycerides. For persons with hypertension and concomitant abdominal obesity is characterized by endothelial dysfunction and significant additional purpose to standard therapy ω-3 polyunsaturated fatty acids leads to a significant improvement. Key Words: arterial hypertension, obesity, dyslipidemia, endothelial function, free-3 polyunsaturated fatty acids.

Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy

2020 ◽  
Vol 194 ◽  
pp. 229-236 ◽  
Author(s):  
Alessandro Di Minno ◽  
Marco Gentile ◽  
Gabriella Iannuzzo ◽  
Ilenia Calcaterra ◽  
Maria Tripaldella ◽  
...  
Keyword(s):  
Endothelial Function ◽  
Familial Hypercholesterolemia ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy

scholarly journals Low Levels of Low-Density Lipoprotein Cholesterol and Endothelial Function in Subjects without Lipid-Lowering Therapy

2020 ◽  
Vol 9 (12) ◽  
pp. 3796
Author(s):  
Yuji Takaeko ◽  
Masato Kajikawa ◽  
Shinji Kishimoto ◽  
Takayuki Yamaji ◽  
Takahiro Harada ◽  
...  
Keyword(s):  
Endothelial Function ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Low Density Lipoprotein Cholesterol ◽  
Lowering Therapy ◽  
Low Levels ◽  
Relationship Of ◽  
The Relationship

An elevation of serum low-density lipoprotein cholesterol (LDL-C) levels has been associated with endothelial dysfunction in statin naïve subjects. However, there is no information on endothelial function in subjects with extremely low levels of LDL-C. The purpose of the present study was to determine the relationship of LDL-C levels, especially low levels of LDL-C, with endothelial function. Endothelial function assessed by flow-mediated vasodilation (FMD) measurement and LDL-C levels were evaluated in 7120 subjects without lipid-lowering therapy. We divided the subjects into five groups by LDL-C levels: <70 mg/dL, 70–99 mg/dL, 100–119 md/dL, 120–139 mg/dL, and ≥140 mg/dL. FMD values were significantly smaller in subjects with LDL-C levels of ≥140 mg/dL than in those with LDL-C levels of 70–99 mg/dL and 100–119 mg/dL (p < 0.001 and p = 0.004, respectively). The FMD values in the LDL-C of <70 mg/dL group were not significantly different from those in the other groups. To evaluate the relationship of extremely low LDL-C levels with endothelial function, we divided the subjects with LDL-C of <70 mg/dL into those with LDL-C levels of <50 mg/dL and 50–69 mg/dL. FMD values were similar in the LDL-C <50 mg/dL group and ≥50 mg/dL group in the propensity score-matched population (p = 0.570). A significant benefit was not found in subjects with low LDL-C levels from the aspect of endothelial function.

Sign in / Sign up

Export Citation Format

Share Document